25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LABB (Genomma Lab Internacional S.A.B. de C.V) Stock Analysis
Buy, Hold or Sell?

Let's analyze Genomma Lab Internacional S.A.B. de C.V together

I guess you are interested in Genomma Lab Internacional S.A.B. de C.V. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • šŸ“Š Fundamental Analysis (FA) – Genomma Lab Internacional S.A.B. de C.V’s Financial Insights
  • šŸ“ˆ Technical Analysis (TA) – Genomma Lab Internacional S.A.B. de C.V’s Price Targets

I'm going to help you getting a better view of Genomma Lab Internacional S.A.B. de C.V. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genomma Lab Internacional S.A.B. de C.V

I send you an email if I find something interesting about Genomma Lab Internacional S.A.B. de C.V.

1. Quick Overview

1.1. Quick analysis of Genomma Lab Internacional S.A.B. de C.V (30 sec.)










1.2. What can you expect buying and holding a share of Genomma Lab Internacional S.A.B. de C.V? (30 sec.)

How much money do you get?

How much money do you get?
₱0.04
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
₱11.36
Expected worth in 1 year
₱12.69
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
₱2.13
Return On Investment
10.2%

For what price can you sell your share?

Current Price per Share
₱20.79
Expected price per share
₱20.15 - ₱25.72
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genomma Lab Internacional S.A.B. de C.V (5 min.)




Live pricePrice per Share (EOD)
₱20.79
Intrinsic Value Per Share
₱-41.39 - ₱5.08
Total Value Per Share
₱-30.03 - ₱16.44

2.2. Growth of Genomma Lab Internacional S.A.B. de C.V (5 min.)




Is Genomma Lab Internacional S.A.B. de C.V growing?

Current yearPrevious yearGrowGrow %
How rich?$586.5m$531.9m$45.2m7.8%

How much money is Genomma Lab Internacional S.A.B. de C.V making?

Current yearPrevious yearGrowGrow %
Making money$29.8m$14.5m$15.3m51.5%
Net Profit Margin12.0%6.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Genomma Lab Internacional S.A.B. de C.V (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genomma Lab Internacional S.A.B. de C.V?

Welcome investor! Genomma Lab Internacional S.A.B. de C.V's management wants to use your money to grow the business. In return you get a share of Genomma Lab Internacional S.A.B. de C.V.

First you should know what it really means to hold a share of Genomma Lab Internacional S.A.B. de C.V. And how you can make/lose money.

Speculation

The Price per Share of Genomma Lab Internacional S.A.B. de C.V is ₱20.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genomma Lab Internacional S.A.B. de C.V.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genomma Lab Internacional S.A.B. de C.V, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₱11.36. Based on the TTM, the Book Value Change Per Share is ₱0.33 per quarter. Based on the YOY, the Book Value Change Per Share is ₱-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₱0.20 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genomma Lab Internacional S.A.B. de C.V.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 ā‚±% of Price per Share₱% of Price per Share₱% of Price per Share₱% of Price per Share₱% of Price per Share₱% of Price per Share
Usd Eps0.030.1%0.030.1%0.010.1%0.020.1%0.020.1%0.020.1%
Usd Book Value Change Per Share0.010.1%0.020.1%0.000.0%0.000.0%0.010.0%0.000.0%
Usd Dividend Per Share0.010.1%0.010.1%0.010.1%0.010.1%0.010.1%0.010.0%
Usd Total Gains Per Share0.020.1%0.030.1%0.010.0%0.020.1%0.020.1%0.010.0%
Usd Price Per Share1.34-1.19-0.75-0.93-1.00-0.98-
Price to Earnings Ratio12.42-10.09--7.38-4.91-9.38-21.88-
Price-to-Total Gains Ratio59.05--21.06-18.58--33.90-52.88-17.54-
Price to Book Ratio2.23-2.01-1.37-1.64-1.85-2.08-
Price-to-Total Gains Ratio59.05--21.06-18.58--33.90-52.88-17.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.097712
Number of shares910
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.020.01
Usd Total Gains Per Share0.030.02
Gains per Quarter (910 shares)25.5418.69
Gains per Year (910 shares)102.1774.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1396492453065
2771271949059140
311619129613689215
4154255398181118290
5193318500226148365
6231382602271177440
7270445704316207515
8308509806361236590
9347573908407266665
103856361010452296740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%38.01.01.095.0%67.01.01.097.1%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%15.05.00.075.0%27.013.00.067.5%54.013.02.078.3%
Dividend per Share4.00.00.0100.0%11.00.01.091.7%16.00.04.080.0%16.00.024.040.0%19.00.050.027.5%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%16.04.00.080.0%28.012.00.070.0%56.012.01.081.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genomma Lab Internacional S.A.B. de C.V compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2290.331-31%-0.077+133%0.085+171%0.154+49%0.013+1642%
Book Value Per Share--11.36211.203+1%10.345+10%10.715+6%10.322+10%9.237+23%
Current Ratio--1.5551.771-12%1.656-6%1.587-2%1.631-5%1.419+10%
Debt To Asset Ratio--0.5390.528+2%0.531+2%0.525+3%0.537+0%0.546-1%
Debt To Equity Ratio--1.1681.117+5%1.132+3%1.106+6%1.164+0%1.226-5%
Dividend Per Share--0.2000.2000%0.198+1%0.230-13%0.235-15%0.118+70%
Enterprise Value--11794956029.7809811885185.510+20%2388845126.800+394%5738607686.082+106%7037392289.374+68%7371118802.171+60%
Eps--0.5100.580-12%0.282+81%0.405+26%0.378+35%0.322+58%
Ev To Sales Ratio--0.6690.524+28%0.147+354%0.322+108%0.433+54%0.527+27%
Free Cash Flow Per Share---0.2630.695-138%0.449-158%0.493-153%0.469-156%0.517-151%
Free Cash Flow To Equity Per Share---0.2630.695-138%0.449-158%0.397-166%0.316-183%0.385-168%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--5.078----------
Intrinsic Value_10Y_min---41.391----------
Intrinsic Value_1Y_max--1.845----------
Intrinsic Value_1Y_min--0.937----------
Intrinsic Value_3Y_max--4.525----------
Intrinsic Value_3Y_min---1.571----------
Intrinsic Value_5Y_max--5.977----------
Intrinsic Value_5Y_min---8.869----------
Market Cap20245156968.960-22%24766475029.78022028459435.510+12%13766998876.800+80%17358705019.415+43%18935936039.374+31%18320357552.171+35%
Net Profit Margin--0.1130.120-6%0.063+80%0.090+26%0.091+25%0.089+27%
Operating Margin----0%-0%0.064-100%0.119-100%0.130-100%
Operating Ratio--1.1541.149+0%1.172-2%1.177-2%1.178-2%1.034+12%
Pb Ratio1.830-22%2.2292.011+11%1.373+62%1.642+36%1.853+20%2.075+7%
Pe Ratio10.190-22%12.41510.090+23%-7.384+159%4.910+153%9.380+32%21.881-43%
Price Per Share20.790-22%25.33022.570+12%14.138+79%17.686+43%19.014+33%18.490+37%
Price To Free Cash Flow Ratio-19.773+18%-24.091-1.072-96%-1.290-95%4.113-686%-9.736-60%-58.259+142%
Price To Total Gains Ratio48.468-22%59.052-21.064+136%18.584+218%-33.904+157%52.877+12%17.535+237%
Quick Ratio--0.6400.708-10%0.635+1%0.716-11%0.849-25%0.957-33%
Return On Assets--0.0210.025-16%0.013+64%0.018+15%0.017+22%0.016+30%
Return On Equity--0.0450.052-13%0.027+69%0.038+19%0.037+23%0.035+27%
Total Gains Per Share--0.4290.532-19%0.122+253%0.315+36%0.389+10%0.131+228%
Usd Book Value--586547649.600577169406.000+2%531900930.000+10%555505724.400+6%541726479.360+8%482916254.040+21%
Usd Book Value Change Per Share--0.0120.017-31%-0.004+133%0.004+171%0.008+49%0.001+1642%
Usd Book Value Per Share--0.6000.591+1%0.546+10%0.566+6%0.545+10%0.488+23%
Usd Dividend Per Share--0.0110.0110%0.010+1%0.012-13%0.012-15%0.006+70%
Usd Enterprise Value--622773678.372518067537.795+20%126131022.695+394%302998485.825+106%371574312.879+68%389195072.755+60%
Usd Eps--0.0270.031-12%0.015+81%0.021+26%0.020+35%0.017+58%
Usd Free Cash Flow---13570233.60035757084.000-138%23110718.400-159%25442542.400-153%24528686.160-155%26825232.720-151%
Usd Free Cash Flow Per Share---0.0140.037-138%0.024-158%0.026-153%0.025-156%0.027-151%
Usd Free Cash Flow To Equity Per Share---0.0140.037-138%0.024-158%0.021-166%0.017-183%0.020-168%
Usd Market Cap1068944287.961-22%1307669881.5721163102658.195+12%726897540.695+80%916539625.025+43%999817422.879+31%967314878.755+35%
Usd Price Per Share1.098-22%1.3371.192+12%0.746+79%0.934+43%1.004+33%0.976+37%
Usd Profit--26332363.20029883704.400-12%14507011.200+82%21263915.200+24%20001973.200+32%16912830.000+56%
Usd Revenue--232654012.800248369998.800-6%217618077.600+7%230056015.200+1%217332553.680+7%190065179.040+22%
Usd Total Gains Per Share--0.0230.028-19%0.006+253%0.017+36%0.021+10%0.007+228%
 EOD+3 -5MRQTTM+11 -26YOY+26 -113Y+23 -155Y+23 -1510Y+28 -11

3.3 Fundamental Score

Let's check the fundamental score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.190
Price to Book Ratio (EOD)Between0-11.830
Net Profit Margin (MRQ)Greater than00.113
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.640
Current Ratio (MRQ)Greater than11.555
Debt to Asset Ratio (MRQ)Less than10.539
Debt to Equity Ratio (MRQ)Less than11.168
Return on Equity (MRQ)Greater than0.150.045
Return on Assets (MRQ)Greater than0.050.021
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose20.810
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Genomma Lab Internacional S.A.B. de C.V

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Fundamental data was last updated by Penke on 2025-06-08 13:42:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Genomma Lab Internacional S.A.B. de C.V earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.3%Ā means thatĀ $0.11 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 11.3%. The company is making a huge profit. +2
  • The TTM is 12.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.3%TTM12.0%-0.7%
TTM12.0%YOY6.3%+5.7%
TTM12.0%5Y9.1%+2.9%
5Y9.1%10Y8.9%+0.2%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Genomma Lab Internacional S.A.B. de C.V is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • 2.1% Return on Assets means thatĀ Genomma Lab Internacional S.A.B. de C.V generatedĀ $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 2.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM2.5%-0.4%
TTM2.5%YOY1.3%+1.2%
TTM2.5%5Y1.7%+0.8%
5Y1.7%10Y1.6%+0.1%
4.3.1.3. Return on Equity

Shows how efficient Genomma Lab Internacional S.A.B. de C.V is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • 4.5% Return on Equity means Genomma Lab Internacional S.A.B. de C.V generated $0.04Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 4.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 5.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.5%TTM5.2%-0.7%
TTM5.2%YOY2.7%+2.5%
TTM5.2%5Y3.7%+1.5%
5Y3.7%10Y3.5%+0.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genomma Lab Internacional S.A.B. de C.V.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Genomma Lab Internacional S.A.B. de C.V is operatingĀ .

  • Measures how much profit Genomma Lab Internacional S.A.B. de C.V makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Ā means the company generated $0.00 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y11.9%-11.9%
5Y11.9%10Y13.0%-1.1%
4.3.2.2. Operating Ratio

Measures how efficient Genomma Lab Internacional S.A.B. de C.V is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.15 means that the operating costs are $1.15 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.154. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.149. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.154TTM1.149+0.005
TTM1.149YOY1.172-0.023
TTM1.1495Y1.178-0.029
5Y1.17810Y1.034+0.145
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genomma Lab Internacional S.A.B. de C.V.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.56Ā means the company has $1.56 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.555. The company is able to pay all its short-term debts. +1
  • The TTM is 1.771. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.555TTM1.771-0.216
TTM1.771YOY1.656+0.116
TTM1.7715Y1.631+0.140
5Y1.63110Y1.419+0.212
4.4.3.2. Quick Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.64Ā means the company can pay off $0.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.640. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.708. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.640TTM0.708-0.068
TTM0.708YOY0.635+0.073
TTM0.7085Y0.849-0.141
5Y0.84910Y0.957-0.108
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genomma Lab Internacional S.A.B. de C.V.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of Genomma Lab Internacional S.A.B. de C.VĀ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Genomma Lab Internacional S.A.B. de C.V to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.54Ā means that Genomma Lab Internacional S.A.B. de C.V assets areĀ financed with 53.9% credit (debt) and the remaining percentage (100% - 53.9%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.539. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.528. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.539TTM0.528+0.011
TTM0.528YOY0.531-0.003
TTM0.5285Y0.537-0.009
5Y0.53710Y0.546-0.009
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Genomma Lab Internacional S.A.B. de C.V is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 116.8% means that company has $1.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.168. The company is able to pay all its debts with equity. +1
  • The TTM is 1.117. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.168TTM1.117+0.051
TTM1.117YOY1.132-0.015
TTM1.1175Y1.164-0.047
5Y1.16410Y1.226-0.061
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Genomma Lab Internacional S.A.B. de C.V generates.

  • Above 15 is considered overpriced butĀ always compareĀ Genomma Lab Internacional S.A.B. de C.V to theĀ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 12.42 means the investor is paying $12.42Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 10.190. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.415. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.090. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD10.190MRQ12.415-2.225
MRQ12.415TTM10.090+2.325
TTM10.090YOY-7.384+17.474
TTM10.0905Y9.380+0.711
5Y9.38010Y21.881-12.501
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is -19.773. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -24.091. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.072. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.773MRQ-24.091+4.318
MRQ-24.091TTM-1.072-23.019
TTM-1.072YOY-1.290+0.218
TTM-1.0725Y-9.736+8.664
5Y-9.73610Y-58.259+48.523
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Genomma Lab Internacional S.A.B. de C.V is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.23 means the investor is paying $2.23Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 1.830. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.229. Based on the equity, the company is underpriced. +1
  • The TTM is 2.011. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.830MRQ2.229-0.400
MRQ2.229TTM2.011+0.218
TTM2.011YOY1.373+0.639
TTM2.0115Y1.853+0.158
5Y1.85310Y2.075-0.223
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in MXN. All numbers in thousands.

Summary
Total Assets24,080,376
Total Liabilities12,971,519
Total Stockholder Equity11,108,857
 As reported
Total Liabilities 12,971,519
Total Stockholder Equity+ 11,108,857
Total Assets = 24,080,376

Assets

Total Assets24,080,376
Total Current Assets13,053,358
Long-term Assets11,027,018
Total Current Assets
Cash And Cash Equivalents 2,157,025
Net Receivables 5,371,263
Inventory 2,229,596
Total Current Assets  (as reported)13,053,358
Total Current Assets  (calculated)9,757,884
+/- 3,295,474
Long-term Assets
Property Plant Equipment 3,653,478
Intangible Assets 5,770,100
Long-term Assets Other 1,603,440
Long-term Assets  (as reported)11,027,018
Long-term Assets  (calculated)11,027,018
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,392,563
Long-term Liabilities4,578,956
Total Stockholder Equity11,108,857
Total Current Liabilities
Short Long Term Debt 2,959,073
Accounts payable 1,985,557
Other Current Liabilities 3,278,586
Total Current Liabilities  (as reported)8,392,563
Total Current Liabilities  (calculated)8,223,216
+/- 169,347
Long-term Liabilities
Long term Debt 3,998,252
Long-term Liabilities Other 580,704
Long-term Liabilities  (as reported)4,578,956
Long-term Liabilities  (calculated)4,578,956
+/-0
Total Stockholder Equity
Retained Earnings 11,815,006
Total Stockholder Equity (as reported)11,108,857
Total Stockholder Equity (calculated)11,815,006
+/- 706,149
Other
Capital Stock1,825,350
Common Stock Shares Outstanding 977,753
Net Debt 4,800,300
Net Invested Capital 18,066,182
Net Working Capital 4,660,795
Property Plant and Equipment Gross 3,653,478



6.2. Balance Sheets Structured

Currency in MXN. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-03-312006-12-312005-12-31
> Total Assets 
475,694
734,614
0
1,194,030
0
2,503,613
2,695,824
2,839,928
2,881,319
3,294,216
3,755,947
4,241,650
4,370,461
4,594,557
5,150,362
5,830,909
6,846,851
7,338,810
8,123,014
9,193,972
8,873,330
10,532,531
11,716,573
12,992,590
13,127,881
13,890,790
15,058,077
17,352,868
17,465,890
18,318,487
18,594,890
25,428,315
25,241,294
24,765,165
20,532,381
17,633,159
17,700,718
17,712,301
15,282,804
15,708,616
16,025,740
16,142,468
15,867,312
15,885,706
17,697,999
16,742,413
17,306,143
18,077,257
18,885,635
19,412,322
19,105,562
19,254,750
20,906,447
21,101,766
21,781,793
22,132,616
22,654,170
22,869,778
23,230,903
21,542,960
22,163,844
22,014,252
21,827,930
21,606,530
21,844,365
21,679,835
22,078,030
20,738,487
21,311,788
21,984,814
23,508,259
23,017,803
24,080,376
24,080,37623,017,80323,508,25921,984,81421,311,78820,738,48722,078,03021,679,83521,844,36521,606,53021,827,93022,014,25222,163,84421,542,96023,230,90322,869,77822,654,17022,132,61621,781,79321,101,76620,906,44719,254,75019,105,56219,412,32218,885,63518,077,25717,306,14316,742,41317,697,99915,885,70615,867,31216,142,46816,025,74015,708,61615,282,80417,712,30117,700,71817,633,15920,532,38124,765,16525,241,29425,428,31518,594,89018,318,48717,465,89017,352,86815,058,07713,890,79013,127,88112,992,59011,716,57310,532,5318,873,3309,193,9728,123,0147,338,8106,846,8515,830,9095,150,3624,594,5574,370,4614,241,6503,755,9473,294,2162,881,3192,839,9282,695,8242,503,61301,194,0300734,614475,694
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,818,155
0
8,227,055
8,276,515
8,090,105
7,840,639
9,598,847
8,526,818
8,726,891
8,997,564
9,487,324
10,479,717
9,926,178
9,817,549
11,276,493
11,322,984
11,778,894
12,037,474
12,331,554
12,381,463
12,686,939
11,521,057
12,106,509
11,803,847
11,585,537
11,312,244
11,490,196
11,526,352
11,942,497
10,670,395
11,066,509
11,483,627
12,194,282
12,066,531
13,053,358
13,053,35812,066,53112,194,28211,483,62711,066,50910,670,39511,942,49711,526,35211,490,19611,312,24411,585,53711,803,84712,106,50911,521,05712,686,93912,381,46312,331,55412,037,47411,778,89411,322,98411,276,4939,817,5499,926,17810,479,7179,487,3248,997,5648,726,8918,526,8189,598,8477,840,6398,090,1058,276,5158,227,05507,818,15500000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,591,522
0
1,863,585
1,874,429
1,025,684
1,069,535
2,421,105
1,187,030
1,128,873
1,391,372
1,378,325
1,191,741
1,109,941
899,662
1,346,819
1,186,239
1,567,634
2,048,785
1,824,276
1,408,994
1,755,220
1,220,905
1,553,561
1,299,392
1,093,330
1,496,556
1,249,044
1,369,610
1,763,956
1,472,096
1,142,126
1,233,360
1,829,131
2,275,791
2,157,025
2,157,0252,275,7911,829,1311,233,3601,142,1261,472,0961,763,9561,369,6101,249,0441,496,5561,093,3301,299,3921,553,5611,220,9051,755,2201,408,9941,824,2762,048,7851,567,6341,186,2391,346,819899,6621,109,9411,191,7411,378,3251,391,3721,128,8731,187,0302,421,1051,069,5351,025,6841,874,4291,863,58501,591,52200000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
205,926
0
0
0
183,232
0
0
0
89,248
0
089,248000183,232000205,926000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
250,586
484,893
0
669,005
0
836,609
1,031,746
766,995
891,033
769,974
1,298,452
1,576,442
1,667,488
1,972,440
2,340,912
2,209,635
2,311,473
2,943,802
2,509,219
3,655,160
4,084,107
4,142,061
4,580,362
5,266,837
4,919,382
4,583,609
4,996,055
5,693,555
5,470,983
6,006,698
6,517,227
5,471,405
4,687,240
4,683,666
5,178,353
3,919,520
3,988,690
3,907,208
4,270,795
4,361,897
4,670,309
4,592,864
5,158,942
5,005,618
5,386,113
5,270,221
5,264,267
5,319,176
3,186,979
3,469,504
3,314,220
6,305,406
6,969,308
7,128,254
6,977,408
7,310,878
7,503,998
7,805,738
7,845,310
7,399,912
7,450,788
7,049,126
6,757,263
6,764,163
7,120,374
4,538,830
4,304,510
3,743,154
4,574,302
4,842,027
4,764,136
4,444,414
5,371,263
5,371,2634,444,4144,764,1364,842,0274,574,3023,743,1544,304,5104,538,8307,120,3746,764,1636,757,2637,049,1267,450,7887,399,9127,845,3107,805,7387,503,9987,310,8786,977,4087,128,2546,969,3086,305,4063,314,2203,469,5043,186,9795,319,1765,264,2675,270,2215,386,1135,005,6185,158,9424,592,8644,670,3094,361,8974,270,7953,907,2083,988,6903,919,5205,178,3534,683,6664,687,2405,471,4056,517,2276,006,6985,470,9835,693,5554,996,0554,583,6094,919,3825,266,8374,580,3624,142,0614,084,1073,655,1602,509,2192,943,8022,311,4732,209,6352,340,9121,972,4401,667,4881,576,4421,298,452769,974891,033766,9951,031,746836,6090669,0050484,893250,586
       Other Current Assets 
31,411
15,048
0
42,807
0
32,908
49,623
127,394
53,668
102,439
72,526
85,404
95,743
66,226
83,440
73,308
290,198
209,841
206,525
333,885
181,157
319,163
451,653
999,261
1,143,582
1,137,551
866,904
1,084,498
1,130,145
1,218,874
1,195,742
8,889,496
8,845,880
8,589,151
1,969,325
734,665
799,070
1,269,544
763,474
416,199
592,599
582,455
545,172
478,069
666,395
871,127
843,591
589,984
416,092
954,453
620,686
704,638
863,667
792,025
734,982
631,828
666,882
657,064
644,681
698,368
682,142
938,171
876,078
654,486
0
0
0
0
0
0
0
0
0
000000000654,486876,078938,171682,142698,368644,681657,064666,882631,828734,982792,025863,667704,638620,686954,453416,092589,984843,591871,127666,395478,069545,172582,455592,599416,199763,4741,269,544799,070734,6651,969,3258,589,1518,845,8808,889,4961,195,7421,218,8741,130,1451,084,498866,9041,137,5511,143,582999,261451,653319,163181,157333,885206,525209,841290,19873,30883,44066,22695,74385,40472,526102,43953,668127,39449,62332,908042,807015,04831,411
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,398,311
8,932,605
9,179,384
9,437,201
9,629,954
9,778,782
9,902,899
10,095,142
10,322,616
10,488,315
10,543,964
10,021,903
10,057,335
10,210,405
10,242,393
10,294,286
10,354,169
10,153,483
10,135,533
10,068,092
10,245,279
10,501,187
11,313,977
10,951,272
11,027,018
11,027,01810,951,27211,313,97710,501,18710,245,27910,068,09210,135,53310,153,48310,354,16910,294,28610,242,39310,210,40510,057,33510,021,90310,543,96410,488,31510,322,61610,095,1429,902,8999,778,7829,629,9549,437,2019,179,3848,932,6059,398,311000000000000000000000000000000000000000000000000
       Property Plant Equipment 
25,004
25,231
0
44,298
0
65,535
99,560
107,718
107,949
138,613
163,245
260,698
396,934
385,176
407,072
424,996
423,989
429,144
436,958
427,763
430,455
422,478
439,041
403,588
395,866
392,699
387,104
408,383
432,344
431,622
441,888
457,659
423,645
407,078
407,291
406,645
379,684
325,154
324,145
412,811
364,293
369,640
356,500
548,649
647,082
859,024
1,149,171
1,870,234
2,169,829
1,837,787
2,139,073
2,220,748
2,323,961
2,467,356
2,583,429
2,852,165
3,006,415
3,121,197
3,244,776
3,366,118
3,423,790
3,473,626
3,499,200
3,592,621
3,650,902
3,449,769
3,439,002
3,414,811
3,460,349
3,499,391
3,503,018
3,558,571
3,653,478
3,653,4783,558,5713,503,0183,499,3913,460,3493,414,8113,439,0023,449,7693,650,9023,592,6213,499,2003,473,6263,423,7903,366,1183,244,7763,121,1973,006,4152,852,1652,583,4292,467,3562,323,9612,220,7482,139,0731,837,7872,169,8291,870,2341,149,171859,024647,082548,649356,500369,640364,293412,811324,145325,154379,684406,645407,291407,078423,645457,659441,888431,622432,344408,383387,104392,699395,866403,588439,041422,478430,455427,763436,958429,144423,989424,996407,072385,176396,934260,698163,245138,613107,949107,71899,56065,535044,298025,23125,004
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,998
44,998
44,998
0
44,998
51,950
51,950
0
51,950
51,950
155,293
51,950
51,950
51,950
51,950
52,367
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90,804
0
090,804000000000000000000052,36751,95051,95051,95051,950155,29351,95051,950051,95051,95044,998044,99844,99844,998000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,382,470
0
1,432,839
1,434,572
1,437,498
1,472,805
1,483,581
1,488,900
1,525,846
1,555,834
1,565,996
1,585,698
1,582,108
1,600,702
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,600,7021,582,1081,585,6981,565,9961,555,8341,525,8461,488,9001,483,5811,472,8051,437,4981,434,5721,432,83901,382,47000000000000000000000000000000000000000
       Intangible Assets 
5,621
6,479
0
68,210
0
69,422
78,704
80,523
80,517
435,510
435,510
530,780
454,573
577,335
575,151
659,119
1,626,585
1,630,964
1,810,079
2,076,054
2,095,715
2,967,027
3,533,342
3,469,454
3,870,897
4,186,938
4,828,386
4,716,070
6,498,757
6,508,483
6,573,104
5,261,790
7,100,107
7,118,555
7,188,116
5,402,398
6,470,529
6,556,998
5,407,612
5,066,100
5,259,590
5,229,616
5,245,906
5,117,137
5,198,114
5,250,112
5,226,909
4,934,397
4,821,824
4,823,098
4,747,335
4,913,215
4,937,800
4,922,788
4,901,213
4,908,365
4,884,118
4,897,089
4,952,167
5,169,138
4,986,706
5,017,837
5,030,610
5,151,083
4,976,553
5,119,159
5,112,579
4,961,537
5,092,672
5,211,297
5,869,345
5,926,549
5,770,100
5,770,1005,926,5495,869,3455,211,2975,092,6724,961,5375,112,5795,119,1594,976,5535,151,0835,030,6105,017,8374,986,7065,169,1384,952,1674,897,0894,884,1184,908,3654,901,2134,922,7884,937,8004,913,2154,747,3354,823,0984,821,8244,934,3975,226,9095,250,1125,198,1145,117,1375,245,9065,229,6165,259,5905,066,1005,407,6126,556,9986,470,5295,402,3987,188,1167,118,5557,100,1075,261,7906,573,1046,508,4836,498,7574,716,0704,828,3864,186,9383,870,8973,469,4543,533,3422,967,0272,095,7152,076,0541,810,0791,630,9641,626,585659,119575,151577,335454,573530,780435,510435,51080,51780,52378,70469,422068,21006,4795,621
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,870
8,932,605
9,179,384
92,075
9,629,954
0
0
93,515
0
0
0
220,885
0
0
0
168,900
963,703
0
0
350,979
0
0
0
216,277
1,603,440
1,603,440216,277000350,97900963,703168,900000220,88500093,515009,629,95492,0759,179,3848,932,60566,870000000000000000000000000000000000000000000000000
> Total Liabilities 
310,768
388,542
0
606,590
0
615,864
614,323
527,789
497,932
819,007
1,080,912
1,190,916
1,223,788
1,206,698
1,504,438
1,719,266
2,610,840
2,854,793
3,177,801
3,621,072
3,231,327
4,739,672
5,439,980
5,973,766
6,008,692
6,377,978
7,068,874
8,517,424
8,459,808
8,991,557
9,116,106
14,925,208
14,689,648
13,898,186
9,486,402
8,384,509
8,320,380
8,238,945
8,465,860
8,915,718
9,115,149
9,829,759
9,267,896
8,837,038
10,453,504
9,060,601
9,709,919
10,649,437
11,282,418
11,491,121
11,088,194
11,280,642
12,222,997
12,162,510
12,451,052
12,498,429
12,793,422
12,734,885
12,636,100
11,470,734
11,782,575
11,236,185
10,907,047
11,454,030
11,464,994
11,219,738
11,458,021
11,297,139
11,537,717
11,406,616
12,355,215
12,132,947
12,971,519
12,971,51912,132,94712,355,21511,406,61611,537,71711,297,13911,458,02111,219,73811,464,99411,454,03010,907,04711,236,18511,782,57511,470,73412,636,10012,734,88512,793,42212,498,42912,451,05212,162,51012,222,99711,280,64211,088,19411,491,12111,282,41810,649,4379,709,9199,060,60110,453,5048,837,0389,267,8969,829,7599,115,1498,915,7188,465,8608,238,9458,320,3808,384,5099,486,40213,898,18614,689,64814,925,2089,116,1068,991,5578,459,8088,517,4247,068,8746,377,9786,008,6925,973,7665,439,9804,739,6723,231,3273,621,0723,177,8012,854,7932,610,8401,719,2661,504,4381,206,6981,223,7881,190,9161,080,912819,007497,932527,789614,323615,8640606,5900388,542310,768
   > Total Current Liabilities 
297,848
366,518
0
579,183
0
607,352
605,428
523,024
492,288
654,329
915,355
1,029,329
1,087,100
1,073,540
1,399,693
1,547,746
2,203,733
1,582,463
1,947,808
2,185,524
1,798,294
2,097,264
2,070,720
2,629,900
3,195,840
3,253,416
2,398,219
3,154,086
2,443,414
2,456,608
2,664,198
7,595,888
6,932,988
6,170,895
2,958,714
2,496,069
2,449,775
2,384,265
4,573,545
5,100,403
5,321,796
5,456,035
6,720,078
6,305,022
5,509,600
3,651,594
3,596,934
4,485,318
6,283,204
6,304,192
5,472,886
5,678,539
6,614,317
9,225,414
6,646,737
6,613,971
7,021,927
7,097,036
7,145,307
6,571,141
6,974,629
7,060,830
9,314,740
9,356,443
9,498,662
6,981,800
6,812,912
6,622,353
6,886,335
6,142,548
6,719,150
6,538,418
8,392,563
8,392,5636,538,4186,719,1506,142,5486,886,3356,622,3536,812,9126,981,8009,498,6629,356,4439,314,7407,060,8306,974,6296,571,1417,145,3077,097,0367,021,9276,613,9716,646,7379,225,4146,614,3175,678,5395,472,8866,304,1926,283,2044,485,3183,596,9343,651,5945,509,6006,305,0226,720,0785,456,0355,321,7965,100,4034,573,5452,384,2652,449,7752,496,0692,958,7146,170,8956,932,9887,595,8882,664,1982,456,6082,443,4143,154,0862,398,2193,253,4163,195,8402,629,9002,070,7202,097,2641,798,2942,185,5241,947,8081,582,4632,203,7331,547,7461,399,6931,073,5401,087,1001,029,329915,355654,329492,288523,024605,428607,3520579,1830366,518297,848
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
507,576
1,952,456
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,952,456507,5761,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
1,550,006
1,952,456
4,479,627
1,873,827
1,970,239
2,048,127
2,064,651
2,331,623
2,072,309
1,702,726
0
4,138,224
4,826,146
4,724,471
2,542,792
0
1,985,967
0
0
0
1,364,832
2,959,073
2,959,0731,364,8320001,985,96702,542,7924,724,4714,826,1464,138,22401,702,7262,072,3092,331,6232,064,6512,048,1271,970,2391,873,8274,479,6271,952,4561,550,0061,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Accounts payable 
161,090
114,262
0
78,859
0
261,232
288,363
377,298
307,930
411,192
564,616
594,360
585,132
606,339
723,311
969,099
1,017,730
823,824
833,303
1,262,328
828,342
1,213,283
1,064,676
1,218,663
1,038,471
1,222,130
1,517,129
1,644,125
1,390,111
1,441,339
1,490,297
1,554,690
1,160,518
1,037,835
1,100,611
670,116
685,237
884,912
1,061,085
1,033,545
934,436
1,047,279
1,290,817
1,098,471
1,169,527
1,258,836
1,534,980
1,774,441
2,007,226
1,946,071
1,971,691
1,881,177
1,714,008
1,861,594
1,749,172
1,644,766
1,972,666
2,039,209
1,781,774
1,439,640
1,796,439
1,977,589
2,095,397
1,790,380
1,595,271
1,876,672
1,990,300
1,839,397
1,910,354
1,773,987
1,892,074
1,734,610
1,985,557
1,985,5571,734,6101,892,0741,773,9871,910,3541,839,3971,990,3001,876,6721,595,2711,790,3802,095,3971,977,5891,796,4391,439,6401,781,7742,039,2091,972,6661,644,7661,749,1721,861,5941,714,0081,881,1771,971,6911,946,0712,007,2261,774,4411,534,9801,258,8361,169,5271,098,4711,290,8171,047,279934,4361,033,5451,061,085884,912685,237670,1161,100,6111,037,8351,160,5181,554,6901,490,2971,441,3391,390,1111,644,1251,517,1291,222,1301,038,4711,218,6631,064,6761,213,283828,3421,262,328833,303823,8241,017,730969,099723,311606,339585,132594,360564,616411,192307,930377,298288,363261,232078,8590114,262161,090
       Other Current Liabilities 
92,370
140,799
0
243,574
0
344,609
316,451
145,726
184,358
243,137
350,739
434,969
501,968
467,201
676,382
578,647
1,186,003
758,639
1,114,505
923,196
969,952
883,981
1,006,044
1,004,616
931,944
757,250
820,369
704,936
763,783
717,019
836,446
5,640,619
5,359,513
4,860,117
1,605,671
1,475,069
1,494,124
1,365,902
1,408,740
1,992,950
2,312,923
2,334,319
2,227,810
2,193,496
2,241,590
1,886,566
1,880,620
693,380
1,955,415
2,093,249
1,981,261
563,024
2,797,167
2,737,786
2,864,575
1,108,146
2,786,455
2,791,338
2,823,978
1,131,572
3,439,979
3,035,732
2,898,829
983,242
3,178,920
2,197,437
2,246,467
0
2,627,795
2,635,365
3,324,027
3,282,215
3,278,586
3,278,5863,282,2153,324,0272,635,3652,627,79502,246,4672,197,4373,178,920983,2422,898,8293,035,7323,439,9791,131,5722,823,9782,791,3382,786,4551,108,1462,864,5752,737,7862,797,167563,0241,981,2612,093,2491,955,415693,3801,880,6201,886,5662,241,5902,193,4962,227,8102,334,3192,312,9231,992,9501,408,7401,365,9021,494,1241,475,0691,605,6714,860,1175,359,5135,640,619836,446717,019763,783704,936820,369757,250931,9441,004,6161,006,044883,981969,952923,1961,114,505758,6391,186,003578,647676,382467,201501,968434,969350,739243,137184,358145,726316,451344,6090243,5740140,79992,370
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,999,214
5,186,929
5,615,308
5,602,103
5,608,680
2,937,096
5,804,315
5,884,458
5,771,495
5,637,849
5,490,793
4,899,593
4,807,946
4,175,355
1,592,307
2,097,587
1,966,332
4,237,938
4,645,109
4,674,786
4,651,382
5,264,068
5,636,065
5,594,529
4,578,956
4,578,9565,594,5295,636,0655,264,0684,651,3824,674,7864,645,1094,237,9381,966,3322,097,5871,592,3074,175,3554,807,9464,899,5935,490,7935,637,8495,771,4955,884,4585,804,3152,937,0965,608,6805,602,1035,615,3085,186,9294,999,214000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,881,854
0
-5,817,037
-5,798,999
-3,201,451
-2,073,055
-742,461
-426,022
-85,428
-676,022
-1,925,757
-2,150,196
-1,336,062
-442,406
-1,897,706
0
0
57,612
52,691
0
50,877
56,535
66,512
0
0
63,613
0
0
0
47,044
0
0
0
57,998
0
057,99800047,04400063,6130066,51256,53550,877052,69157,61200-1,897,706-442,406-1,336,062-2,150,196-1,925,757-676,022-85,428-426,022-742,461-2,073,055-3,201,451-5,798,999-5,817,0370-5,881,85400000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
535,724
477,546
502,072
0
502,770
417,573
365,247
676,044
580,704
580,704676,044365,247417,573502,7700502,072477,546535,7240000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
166,593
345,607
346,072
584,580
587,440
1,885,090
2,080,090
2,311,363
2,382,456
2,473,292
2,666,954
3,041,781
3,134,110
3,376,292
3,628,143
4,084,553
4,204,075
4,455,722
4,911,295
5,531,006
5,609,138
5,762,547
6,238,940
6,963,107
7,049,953
7,424,515
7,880,888
8,711,274
8,856,280
9,159,519
9,290,078
10,292,786
10,325,355
10,647,582
10,800,657
8,987,895
9,142,389
9,203,220
6,591,114
6,580,872
6,722,951
6,118,947
6,379,515
6,846,767
7,244,495
7,681,812
7,596,224
7,427,820
7,603,217
7,921,201
8,017,368
7,974,108
8,683,450
8,939,256
9,330,741
9,634,187
9,860,748
10,134,893
10,594,803
10,072,226
10,381,269
10,778,067
10,920,883
10,152,500
10,379,371
10,460,097
10,620,009
9,441,348
9,774,071
10,578,198
11,153,044
10,884,856
11,108,857
11,108,85710,884,85611,153,04410,578,1989,774,0719,441,34810,620,00910,460,09710,379,37110,152,50010,920,88310,778,06710,381,26910,072,22610,594,80310,134,8939,860,7489,634,1879,330,7418,939,2568,683,4507,974,1088,017,3687,921,2017,603,2177,427,8207,596,2247,681,8127,244,4956,846,7676,379,5156,118,9476,722,9516,580,8726,591,1149,203,2209,142,3898,987,89510,800,65710,647,58210,325,35510,292,7869,290,0789,159,5198,856,2808,711,2747,880,8887,424,5157,049,9536,963,1076,238,9405,762,5475,609,1385,531,0064,911,2954,455,7224,204,0754,084,5533,628,1433,376,2923,134,1103,041,7812,666,9542,473,2922,382,4562,311,3632,080,0901,885,090587,440584,580346,072345,607166,593
   Common Stock
266,316
266,316
0
266,316
0
1,703,261
1,795,468
274,923
265,361
265,361
265,361
265,361
265,361
1,921,659
1,921,659
1,921,660
1,921,659
1,921,659
1,921,659
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,912,967
1,914,306
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
0
0
0
0
0
0
0
0
000000001,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,914,3061,912,9671,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6591,921,6591,921,6591,921,6601,921,6591,921,659265,361265,361265,361265,361265,361274,9231,795,4681,703,2610266,3160266,316266,316
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000-1,574,098-1,464,497-749,905-1,660,094-1,657,060-1,657,060-1,658,443-1,656,086-1,285,766-1,108,981-621,541-578,955-468,688-311,151-247,385-74,394-84,142-71,000-74,343-74,621-160,350-157,523-158,012-159,952-163,932-264,082-104,189-96,477-63,333-59,351-48,578-73,898-49,826-26,288-60,118-69,415-64,816-73,951-42,641-41,157-37,717000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
772,356
0
476,396
742,050
772,100
559,478
52,426
865,510
676,469
97,673
424,832
532,635
546,889
52,380
711,096
670,543
600,389
-51,471
406,604
311,188
315,017
-133,427
-44,144
262,184
245,560
-145,369
-83,037
0
0
0
0
0
0
0
0
00000000-83,037-145,369245,560262,184-44,144-133,427315,017311,188406,604-51,471600,389670,543711,09652,380546,889532,635424,83297,673676,469865,51052,426559,478772,100742,050476,3960772,35600000000000000000000000000000000000000



6.3. Balance Sheets

Currency in MXN. All numbers in thousands.




6.4. Cash Flows

Currency in MXN. All numbers in thousands.




6.5. Income Statements

Currency in MXN. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in MXN. All numbers in thousands.

Gross Profit (+$)
totalRevenue18,606,903
Cost of Revenue-6,675,859
Gross Profit11,931,04411,931,044
 
Operating Income (+$)
Gross Profit11,931,044
Operating Expense-14,701,478
Operating Income3,905,425-2,770,434
 
Operating Expense (+$)
Research Development0
Selling General Administrative8,055,036
Selling And Marketing Expenses0
Operating Expense14,701,4788,055,036
 
Net Interest Income (+$)
Interest Income106,111
Interest Expense-887,799
Other Finance Cost-0
Net Interest Income-781,688
 
Pretax Income (+$)
Operating Income3,905,425
Net Interest Income-781,688
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,891,0923,905,425
EBIT - interestExpense = -887,799
1,493,122
2,380,921
Interest Expense887,799
Earnings Before Interest and Taxes (EBIT)03,778,891
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax2,891,092
Tax Provision-799,981
Net Income From Continuing Ops2,091,1112,091,111
Net Income1,493,122
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0781,688
 

Technical Analysis of Genomma Lab Internacional S.A.B. de C.V
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genomma Lab Internacional S.A.B. de C.V. The general trend of Genomma Lab Internacional S.A.B. de C.V is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genomma Lab Internacional S.A.B. de C.V's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Genomma Lab Internacional S.A.B. de C.V Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genomma Lab Internacional S.A.B. de C.V.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 22.88 < 25.48 < 25.72.

The bearish price targets are: 20.62 > 20.48 > 20.15.

Know someone who trades $LABB? Share this with them.šŸ‘‡

Genomma Lab Internacional S.A.B. de C.V Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genomma Lab Internacional S.A.B. de C.V. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genomma Lab Internacional S.A.B. de C.V Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Moving Average Convergence/Divergence (MACD) ChartGenomma Lab Internacional S.A.B. de C.V Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genomma Lab Internacional S.A.B. de C.V. The current adx is .

Genomma Lab Internacional S.A.B. de C.V Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Relative Strength Index (RSI) ChartGenomma Lab Internacional S.A.B. de C.V Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Stochastic Oscillator ChartGenomma Lab Internacional S.A.B. de C.V Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Commodity Channel Index (CCI) ChartGenomma Lab Internacional S.A.B. de C.V Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Chande Momentum Oscillator (CMO) ChartGenomma Lab Internacional S.A.B. de C.V Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Williams %R ChartGenomma Lab Internacional S.A.B. de C.V Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Average True Range (ATR) ChartGenomma Lab Internacional S.A.B. de C.V Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily On-Balance Volume (OBV) ChartGenomma Lab Internacional S.A.B. de C.V Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional S.A.B. de C.V Daily Money Flow Index (MFI) ChartGenomma Lab Internacional S.A.B. de C.V Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genomma Lab Internacional S.A.B. de C.V.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-01-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Genomma Lab Internacional S.A.B. de C.V Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose20.810
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Genomma Lab Internacional S.A.B. de C.V with someone you think should read this too:
  • Are you bullish or bearish on Genomma Lab Internacional S.A.B. de C.V? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genomma Lab Internacional S.A.B. de C.V? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genomma Lab Internacional S.A.B. de C.V

I send you an email if I find something interesting about Genomma Lab Internacional S.A.B. de C.V.


Comments

How you think about this?

Leave a comment

Stay informed about Genomma Lab Internacional S.A.B. de C.V.

Receive notifications about Genomma Lab Internacional S.A.B. de C.V in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.